9 Meters Biopharma Gross Profit

9 Meters Biopharma's gross profit stands at $0 as of March 2023. In the prior-year period, the figure was $0. That is below the Technology sector average of $2.1T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

9 Meters Biopharma reported $0 in gross profit versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

9 Meters Biopharma sits lower the Technology benchmark ($2.1T) with a gross profit of $0. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

In the prior-year period, the figure was $0. Sustained growth in gross profit can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how 9 Meters Biopharma's gross profit evolved across reporting periods, while the comparison chart places NMTR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.